Venous thromboembolism prophylaxis in the patient with rheumatic diseases undergoing orthopedic surgery

Perioperative Management of Patients with Rheumatic Disease

Volumn , Issue , 2013, Pages 45-56

  Galanis, Taki ^a   Merli, Geno J ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Anticoagulation; Antiplatelet therapy; Compression stockings; Deep vein thrombosis; Heparin; Thromboembolism

Indexed keywords

EID: 84912048227     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-2203-7_4     Document Type: Chapter

References (55)

1. Pedersen AB, Sorensen HT, Mehnart F, et al. Risk factors for venous thromboembolism in patients undergoing total hip replacement and receiving routine thromboprophylaxis. J Bone Joint Surg Am. 2010;92:2156-64.
2. Sevitt S. Pathology and pathogenesis of deep vein thrombosis. In: Bergan J, Yao J, editors. Venous Problems. Chicago: Year Book; 1976. p. 257-69.
3. Nicolaides A, Kakkar V, Renney J. Soleal sinuses and stasis. Br J Surg. 1970;57:307.
4. Nicolaides A, Kakkar V, Field E, et al. Venous stasis and deep vein thrombosis. Br J Surg. 1972;59:713-6.
5. Stamatakis J, Kakkar V, Sagar S, et al. Femoral vein thrombosis and total hip replacement. BMJ. 1977;2:223-5.
6. Clark C, Cotton L. Blood flow in deep veins of the legs: recording technique and evaluation of method to increase flow during operation. Br J Surg. 1968;55:211-4.
7. Lindstrom B, Ahlman H, Jonsson O, et al. In fluence of anesthesia on blood flow to the calves during surgery. Acta Anesthesiol Scand. 1984;28:201-3.
8. Lindstrom B, Ahlman H, Jonsson O, et al. Blood flow in the calves during surgery. Acta Chir Scand. 1977;143:335-9.
9. Johnson R, Carmichael J, Almond H, et al. Deep venous thrombosis following Charnley arthroplasty. Clin Orthop. 1978;132:24-30.
10. Planes A, Vochelle N, Fagola M. Total hip replacement and deep vein thrombosis: a venographic and necropsy study. J Bone Joint Surg Br. 1990;72:9-13.
11. Comerota A, Stewart G, Alburger P, et al. Operative venodilation: a previously unsuspected factor in the cause of postoperative deep vein thrombosis. Surgery. 1989;106:301-9.
12. Schaub P, Lynch P, Stewart G. The response of canine veins to three types of abdominal surgery: a scanning and transmission electron microscope study. Surgery. 1978;83:411-22.
13. Stewart G, Schaub R, Niewiarowske S. Products of tissue injury: their induction of venous endothelial damage and blood cell adhesion in the dog. Arch Pathol Lab Med. 1980;104:409-13.
14. Stewart G, Alburger P, Stone E, et al. Total hip replacement induces injury to remote veins in a canine model. J Bone Joint Surg Am. 1983;65:97-102.
15. Gitel S, Salvanti E, Wessler S, et al. The effect of total hip replacement and general surgery on antithrombotin III in relation to venous thrombosis. J Bone Joint Surg Am. 1979;61:653-6.
16. Eriksson B, Eriksson E, Erika G, et al. Thrombosis after hip replacement: relationship to the fibrinolytic system. Acta Orthop Scand. 1989;60:159-63.
17. Kluft C, Verheijen J, Jie A, et al. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast acting inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest. 1985;45:605-10.
18. D'Angelo A, Kluft C, Verheijen J, et al. Fibrinolytic shut down after surgery: impairment of the balance between tissue-type plasminogen activator and its speci fic inhibitor. Eur J Clin Invest. 1985;15:308-12.
19. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism. Chest. 2008;133: S381-453.
20. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients. Chest 2012;141(2) (Suppl):287S-325S.
21. Caprini J. Risk assessment as a guide for the prevention of the many faces of venous thromboembolism. Am J Surg. 2010;199:S3-10.
22. Bahl V, Hu HM, Henke PK, et al. A valid study of a retrospective venous thromboembolism risk scoring method. Ann Surg. 2010;2:344-50.
23. Johanson N, Lachiewicz PF, Lieberman JR, et al. Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroscopy. J Am Acad Orthop Surg. 2009;17(17):183-96.
24. White RH, Romano PS, Zhou H, et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med. 1998;158:1525-31.
25. Hull RD, Pineo GF, Stein PD, et al. Extended out of hospital low molecular weight heparin prophylaxis against deep vein thrombosis in patients after elective hips arthroplasty: a systemic review. Ann Intern Med. 2001;135:858-69.
26. Eikelboom JW, Quinlan DJ, Douketis JD. Extended duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta analysis of the randomized trials. Lancet. 2001;358:9-15.
27. Prandoni P, Bruchi O, Sabbion P, et al. Prolonged thromboprophylaxis with oral anticoagulations after total hip arthroplasty: a prospective controlled randomized study. Arch Intern Med. 2002;162:1966-71.
28. Sansone JM, Munoz del Rio A, Anderson A. The prevalence of and speci fic risk factors for venous thromboembolic disease following elective spine surgery. J Bone Joint Surg. 2010;92:304-13.
29. Ettema HB. Low incidence of venographically detected deep vein thrombosis after knee arthroscopy without thromboprophylaxis: a prospective cohort study. J Thromb Haemost. 2006;4:1411-4.
30. Hoppener MR. Low incidence of deep vein thrombosis after knee arthroscopy without thromboprophylaxis: a prospective cohort study of 335 patients. Acta Orthop. 2006;77(5):767-71.
31. Moreno, Hugo Armando Rodriguez. Risk of deep vein thrombosis in patients undergoing knee arthroscopy. Curr Orthop Pract. 2009;20(6):665-8.
32. Ilahi OA. Deep venous thrombosis after knee arthroscopy: a meta-analysis. Arthrosc J Arthrosc Relat Surg. 2005;21(6):727-30.
33. Camporese G. Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy. Ann Intern Med. 2008;149: 73-82.
34. Wirth T. Prevention of venous thromboembolism after knee arthroscopy with low-molecular weight heparin (reviparin): results of a randomized controlled trial. Arthrosc J Arthroscopic Relat Surg. 2001;17(4): 393-9.
35. Michot M. Prevention of deep-vein thrombosis in ambulatory arthroscopic knee surgery: a randomized trial of prophylaxis with low-molecular weight heparin. Arthrosc J Arthrosc Relat Surg. 2002;18(3): 257-63.
36. Ramos J. Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy (Review). Cochrane Database of Systematic Reviews 2008; Issue 4.
37. Galanis T, Thomson L, Palladino M, Merli G. New oral anticoagulants. J Thromb Thrombolysis. 2011;31: 310-20.
38. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37:74-81.
39. Frost C, Yu Z, Moore K, et al. Apixaban, an oral direct factor Xa inhibitor: multiple-dose safety, pharmacokinetics and pharmacodynamics in healthy subjects. J Thromb Haemost. 2007;5:P-M-664.
40. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Eng J Med. 2009;361:594-604.
41. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. ADVANCE-2 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised doubleblind trial. Lancet. 2010;375:807-15.
42. Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus Enoxaparin for thromboprophylaxis after hip replacement. N Eng J Med. 2010;363:2487-98.
43. Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939: an oral, direct Factor Xa inhibitor after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61:873-80.
44. Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78:412-21.
45. Kubitza D, Becka M, Zuehlsdorf M, et al. Effects of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral direct Factor Xa inhibitor, in healthy subjects. J Clin Pharmacol. 2006;46:549-58.
46. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765-75.
47. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358: 2776-86.
48. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372:31-9.
49. Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373: 1673-80.
50. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64:292-303.
51. European Medicines Agency (EMEA). European public assessment report: pradaxa. http://www/emea. europa.eu/humandocs/PFFs/EPAR/pradaxa/ H-829-PI-en.pdf. Accessed 5 Dec 2010.
52. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kalebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Buller HR. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5: 2178-85.
53. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Buller HR. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370: 949-56.
54. Eriksson BI, Dahl OE, Huo MH, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). Thromb Haemost. 2011;105:721-9.
55. Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24: 1-9.